ARCHIVES

Pfizer’s Inlyta Gives FDA a Teaching Moment: Not All PFS Advantages Are Created Equal

This article is from The Cancer Letter archive.

Vol. 37 No. 46 | December 16, 2011

Download PDF Visit The Full Archive

Related Articles

Wanted: Methods To Measure Or Estimate Renal Function For Dosing Cancer Drugs

October 15, 2010

Women’s Caucus Calls For Wide Mammogram Payment

March 18, 1994

In Brief: Bishop No Longer Candidate For NCI Director; HHS Endorses Intramural Scientist Klausner

April 21, 1995

ASCO, ONS Issue Standards For Safe Chemotherapy Administration

October 2, 2009

Letters: Alternatives Needs Scrutiny, Investigator Open-Mindedness

December 3, 1993

NCI Awards $10 Million To States for Cervix Screening

September 27, 1974